Acquisition enhances bioprocess portfolio
Merck acquires Resolution Spectra Systems
Merck enhances its bioprocess portfolio through the acquisition of Resolution Spectra Systems. The company based in France offers Raman spectroscopy analysis through its GMP-ready instrumentation and software. Financial details of the acquisition were not disclosed.
“This acquisition supports our vision of delivering intensified, connected and continuous bioprocessing,” said Andrew Bulpin, head of Process Solutions, Life Science, at Merck. “Raman measurement technology, coupled with the software to analyze and manage the generated data, allows us to offer unique and integrated solutions to help our customers optimize their bioprocesses.”
Christophe Bonneville, co-founder of Resolution Spectra Systems, added, “This acquisition validates our common strategy to support Process Analytical Technology implementation as a key element of biopharmaceutical industry digitalization.”
Resolution Spectra Systems specializes in bioprocessing monitoring sensors based on Raman technology, which: Provide real-time monitoring and process control; measure broad range of bioprocessing parameters, including glucose, lactate, viable cell density and other process-related impurities; monitor all parameters simultaneously with a single probe. This acquisition supports Merck’s recently launched Bio4C™ Software Suite, a first-of-its-kind ecosystem that combines process control, analytics and plant-level automation. The Bio4C™ Software Suite is the latest component of Merck’s expanding BioContinuum™ Platform, which allows for the convergence of intensified process and digital technologies to advance process speed, quality and flexibility, while reducing cost.
Raman technology sensors with the software to manage the data in combination: Raman technology’s bioprocess monitoring sensors complement the “collect” dimension of the Bio4C™ Software Suite, as it provides real-time process analytics across multiple critical process parameters via in-line measurement.
Source: Merck KGaA
Das könnte Sie auch interessieren
Eppendorf posts a strong fiscal year 2019
For the Hamburg-based Eppendorf Group, a globally active life science company, 2019 proved to be a very good fiscal year.
mehr...Thermo Fisher Scientific to Acquire Qiagen
Thermo Fisher Scientific Inc. and Qiagen N.V. announced that their boards of directors, as well as the managing board of Qiagen N.V., have unanimously approved Thermo Fisher’s proposal to acquire Qiagen for €39 per share in cash.
mehr...Agilent to Acquire Biotek
Agilent Technologies Inc. (NYSE: A) announced it has signed a definitive agreement to acquire privately-owned BioTek Instruments for $1.165 billion. With anticipated tax benefits for Agilent, the net purchase price is expected to be approximately...
mehr...Merck Opens Application Phase for Next Accelerator
Merck announced that it has opened the next round of applications for startup companies to participate in the global Merck Accelerator program. Startups can choose to participate in one of the two programs, either at the company’s Innovation Center...
mehr...Stefan Oschmann übergibt 2021 den Vorsitz der Geschäftsleitung an Belén Garijo
Im Jahr 2021 wird Stefan Oschmann den Vorsitz der Geschäftsleitung von Merck an Belén Garijo übergeben. Weiterhin werden neue Mitglieder der Geschäftsleitung die Unternehmensbereiche Healthcare und Life Science verantworten.
mehr...Ausbau der Herstellungskapazitäten
Merck investiert in Antikörper-Wirkstoff-Konjugat-Herstellung
Merck hat eine Investition in Höhe von 59 Mio. Euro für den Ausbau seiner Herstellungskapazitäten für hochaktive Wirkstoffe (HPAPI) und Antikörper-Wirkstoff-Konjugate (ADCs) in den USA bekannt gegeben.
mehr...Sartorius renews its brand focus
Sartorius has revised its brand look today and presents a new logo, new colors and a new brand promise: Simplifying Progress.
mehr...Monitoring organs and cells in living fruit fly larvae
Scientists have developed a method to study processes taking place in the cells of a living fruit fly larva.
mehr...Melting reveals drug targets in a living...
EMBL scientists identify drug targets in blood and organs
Developing new medicines and understanding how they target specific organs often gives a crucial advantage in the fight against human diseases. An international team led by researchers at the European Molecular Biology Laboratory and Cellzome, a GSK...
mehr...